FDA Approves New Indication for Ipsen ’s Somatuline Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome

Paris (France) September 18, 2017 -- Ipsen (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental indication for Somatuline Depot (lanreotide) Injection 120 mg for the...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news